{
  "id": 12803455,
  "title": "Galderma's Nemluvio Shows Sustained Benefits In Inflammatory Skin Diseases Through 3 Years",
  "url": "https://urgent.news/2026/10/08/galdermas-nemluvio-shows-sustained-benefits-in-inflammatory-skin",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T05:46:57.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/galdermas-nemluvio-shows-sustained-benefits-inflammatory-skin-diseases-through-3-years"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Thursday, Galderma (GALD.SW) presented new three-year data from the ARCADIA long-term extension study showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis (AD).",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}